Header

UZH-Logo

Maintenance Infos

Update of the Drug Resistance Mutations in HIV-1: December 2008


Johnson, V A; Brun-Vezinet, F; Clotet, B; Gunthard, H F; Kuritzkes, D R; Pillay, D; Schapiro, J M; Richman, D D (2008). Update of the Drug Resistance Mutations in HIV-1: December 2008. Topics in HIV Medicine, 16(5):138-145.

Abstract

The International AIDS Society-USA (IAS-USA) Drug Resistance Mutations Group reviews new data on HIV-1 drug resistance that have been published or presented at recent scientific meetings to maintain a current list of mutations associated with antiretroviral drug resistance.This December 2008 version of the IAS-USA drug resistance mutations figures updates those published in this journal in March/April 2008 (Johnson VA, Brun-Vezinet F, Clotet B, et al, Top HIV Med, 2008;16:62-68). The compilation includes mutations that may contribute to a reduced virologic response to HIV-1 drugs. It should not be assumed that the list presented here is exhaustive. Drugs that have been approved by the US Food and Drug Administration (US FDA) as well as any drugs available in expanded access programs are included and listed in alphabetical order by drug class. The figures are designed for practitioners to use in identifying key mutations associated with viral resistance to antiretroviral drugs and in making therapeutic decisions. Updates are posted periodically at www.iasusa.org. For more in-depth reading and an extensive reference list, see the 2008 IAS-USA panel recommendations for resistance testing (Hirsch MS, Gunthard HF, Schapiro JM, et al, Clin Infect Dis, 2008:47:266-285).

Abstract

The International AIDS Society-USA (IAS-USA) Drug Resistance Mutations Group reviews new data on HIV-1 drug resistance that have been published or presented at recent scientific meetings to maintain a current list of mutations associated with antiretroviral drug resistance.This December 2008 version of the IAS-USA drug resistance mutations figures updates those published in this journal in March/April 2008 (Johnson VA, Brun-Vezinet F, Clotet B, et al, Top HIV Med, 2008;16:62-68). The compilation includes mutations that may contribute to a reduced virologic response to HIV-1 drugs. It should not be assumed that the list presented here is exhaustive. Drugs that have been approved by the US Food and Drug Administration (US FDA) as well as any drugs available in expanded access programs are included and listed in alphabetical order by drug class. The figures are designed for practitioners to use in identifying key mutations associated with viral resistance to antiretroviral drugs and in making therapeutic decisions. Updates are posted periodically at www.iasusa.org. For more in-depth reading and an extensive reference list, see the 2008 IAS-USA panel recommendations for resistance testing (Hirsch MS, Gunthard HF, Schapiro JM, et al, Clin Infect Dis, 2008:47:266-285).

Statistics

Citations

Dimensions.ai Metrics

214 citations in Scopus®
Google Scholar™

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Infectious Diseases
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Health Sciences > General Medicine
Language:English
Date:December 2008
Deposited On:21 Jan 2009 16:26
Last Modified:29 Jul 2020 17:38
Publisher:International AIDS Society
ISSN:1542-8826
OA Status:Closed
Official URL:http://www.iasusa.org/pub/topics/2008/issue5/138.pdf
PubMed ID:19106428
Full text not available from this repository.